Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $6.96M rose 72.4% year over year, ahead of the +70.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 22.4% from the prior quarter. Over 3 fiscal years it compounded at +213.9% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +72.4% holds above the trailing-twelve-month pace of +70.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 18.86M USD
- Year-over-year change
- +84.2%
- 3-year CAGR
- +213.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.86M | +84.2% |
| FY2024 | 2024-12-31 | 10.24M | +190.4% |
| FY2023 | 2023-12-31 | 3.53M | +478.0% |
| FY2022 | 2022-12-31 | 609.82K | — |
Stock-Based Compensation vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 stock-based compensation of $21.78M is the 5th largest of the 10 companies compared; the peer median is $11.29M.
- Its year-over-year change of +70.4% is the highest of 9, against a peer median of -12.5%.
- Stock-based compensation amounts to 108.9% of revenue for RAPP, versus a peer median of 8.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $96.42M | +5.3% | +35.5% | 12.4% | |
| LTM Jun 2026 | $59.52M | -4.5% | — | 5.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Sep 2026 | $26.2M | -19.6% | +5.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M | +70.4% | +213.9% | 108.9% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M | +31.2% | +73.3% | — |
| LTM Mar 2026 | $7.02M | -5.4% | +66.3% | — | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $1.37M | — | — | — |
| LTM Mar 2026 | $125K | -78.0% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $11.29M | -12.5% | +44.4% | 8.8% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Depreciation & Amortization | 16.36K | 112K | 839K | 1.02M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 609.82K | 3.53M | 10.24M | 18.86M |
| Change in Working Capital | 1.49M | 2.65M | (2.42M) | 3.5M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 856K | (346K) | 2.22M |
| Other Working Capital | 1.49M | 1.8M | (2.07M) | 1.29M |
| Other Non-Cash Items | 5.3M | 1.32M | 4.82M | 636K |
| Operating Cash Flow | (3.24M) | (27.18M) | (64.83M) | (87.47M) |
| Capital Expenditures | (284K) | (1.64M) | (2.41M) | (616K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (77.22M) | (380.74M) | (354.78M) |
| Sales of Investments | 0 | 0 | 209.8M | 167.93M |
| Other Investing Activities | (5M) | 0 | 3.21M | 0 |
| Investing Cash Flow | (5.28M) | (78.86M) | (170.14M) | (187.47M) |
| Debt Repayment | 7.9M | 0 | 0 | 0 |
| Common Stock Issued | 31.79M | 54K | 157.71M | 270.79M |
| Common Stock Repurchased | 0 | (4K) | 0 | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (134K) | 7K | 0 |
| Financing Cash Flow | 39.69M | 145.14M | 221.63M | 270.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.16M | 39.1M | (13.34M) | (4.16M) |
| Free Cash Flow | (3.53M) | (28.82M) | (67.23M) | (88.09M) |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.